Independent Studies Confirm Low Levels of Immune System Protein, Gelsolin, Associated with COVID-19 Severity
August 17, 2020 10:57 ET
|
BioAegis Therapeutics
BioAegis Conducting COVID-19 Clinical Trial of Gelsolin Therapeutic MORRISTOWN, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing...
BioAegis Therapeutics Initiates Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment
August 05, 2020 18:16 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
BioAegis Therapeutics Receives Approval to Proceed with Phase 2 Trial of its Gelsolin COVID-19 Treatment
July 15, 2020 13:34 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., July 15, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., announces that it received regulatory clearance from The Spanish Agency for Medicines and Health Products (AEMPS) for...
BioAegis Therapeutics Completes Over-Subscribed Financing for COVID-19 Trial
June 23, 2020 17:21 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., June 23, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical-stage private company focused on developing therapies for infectious, inflammatory and degenerative...
Study of BioAegis’ Lead Product, Gelsolin, is Key Component of NIAID Strategic Plan for COVID-19 Research
May 21, 2020 13:58 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announces that the National Institute of Health (NIH) Clinical Center is measuring patient gelsolin levels as part of...
BioAegis Demonstrates Gelsolin Therapy Can Quell the Cytokine Storm and Promote Tissue Repair
April 27, 2020 01:15 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., April 27, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. has highlighted recently published gene expression data in animal studies where recombinant human plasma gelsolin...
Small NJ Biotech Firm, BioAegis Therapeutics, Accelerating Multiple Clinical Trial Submissions for Severe COVID-19 Pneumonia Patients
April 02, 2020 02:15 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., April 02, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. is a clinical stage, private company focused on developing therapies for infectious, inflammatory, and degenerative...
BioAegis Therapeutics Announces Publication: "Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Severe Influenza"
December 12, 2019 09:05 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Dec. 12, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical stage company developing technology to address injurious inflammation while protecting immune function and...
BioAegis Therapeutics Named New Jersey’s Most Valuable Venture-Backed Company Led by a Woman
October 22, 2019 16:53 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Oct. 22, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics was recently recognized by PitchBook as the most valuable venture-backed company in New Jersey led by a female entrepreneur....
BioAegis Therapeutics Announces Publication in the Journal of Infectious Diseases: "Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Penicillin-Sensitive and Resistant Pneumococcal Pneumonia"
August 22, 2019 10:15 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Aug. 22, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing technology to control inflammation while protecting immune function and vital...